news
Preventive medicine blurs obesity's heart disease risk, says Lancet review
A new commentary in The Lancet explores how advances in cardiology, like broader screening and cholesterol meds, are shifting the link between obesity and heart disease. While obesity still impacts health, the authors suggest modern prevention might be masking some of its population-level cardiovascular risks. This re-evaluates how we see the direct threat of higher BMI.
A new commentary in The Lancet explores how advances in cardiology, like broader screening and cholesterol meds, are shifting the link between obesity and heart disease. While obesity still impacts health, the authors suggest modern prevention might be masking some of its population-level cardiovascular risks. This re-evaluates how we see the direct threat of higher BMI.
The architecture take
So, are statins and blood pressure meds making us think obesity isn't as big of a deal for your heart? This Lancet piece suggests the medical system's gotten so good at 'preventative' medicine (read: symptom management) that it's actually muddying the waters around the real metabolic impacts of obesity. Your cardiometabolic health is tied to how your body processes energy and fat—inflammation, insulin sensitivity, blood sugar regulation. Statin-shielded arteries might look fine on paper, but the underlying inflammation and metabolic dysfunction could still be driving other issues your doctor isn't catching from a basic lipid panel. It’s less about whether obesity causes disease, and more about what the current medical interventions are hiding. Watch for more nuanced discussions on biological age markers like VO2max and DEXA scans to get a clearer picture of your actual risk, beyond just BMI and cholesterol.